These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31375268)

  • 1. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients.
    Balachandran K; Salawu A; Ghorani E; Kaur B; Sebire NJ; Short D; Harvey R; Hancock B; Tidy J; Singh K; Sarwar N; Winter MC; Seckl MJ
    Gynecol Oncol; 2019 Oct; 155(1):8-12. PubMed ID: 31375268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
    Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
    BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
    Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
    Zhou Y; Feng FZ; Xiang Y; Wan XR
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
    Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
    Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
    Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
    BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
    Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
    Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
    Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
    McGrath S; Short D; Harvey R; Schmid P; Savage PM; Seckl MJ
    Br J Cancer; 2010 Mar; 102(5):810-4. PubMed ID: 20160727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017.
    Kong Y; Zong L; Cheng H; Jiang F; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
    Cancer Med; 2020 Apr; 9(7):2590-2599. PubMed ID: 32022487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors.
    Bakhtiyari M; Mirzamoradi M; Kimyaiee P; Aghaie A; Mansournia MA; Ashrafi-Vand S; Sarfjoo FS
    Fertil Steril; 2015 Sep; 104(3):649-54. PubMed ID: 26099850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
    Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
    Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS
    Gynecol Oncol; 2017 Nov; 147(2):364-370. PubMed ID: 28927899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
    Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
    Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the clinical laboratory detection of gestational trophoblastic disease.
    Seki K; Matsui H; Sekiya S
    Clin Chim Acta; 2004 Nov; 349(1-2):1-13. PubMed ID: 15469850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
    Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
    BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.